Califf: Decades Of Follow-Up Necessary For Gene Therapy
Executive Summary
FDA Commissioner Califf acknowledges that regulatory pathways for gene therapies are still being developed and that many factors outside of the modality impact agency requirements as he emphasized the need for long-term follow up due to the unknowns of gene modification.
You may also be interested in...
Push To Create Ultra-Rare Orphan Drug Designation Finds Resistance At US FDA
Agency officials don’t think a new definition or incentives will fix the issues related to development in rare diseases with only a handful of patients, as advocates continue pushing the idea.
Ultragenyx CEO: FDA Leaders, Review Divisions Out Of Sync On Accelerated Approval For Gene Therapy
In a Pink Sheet interview Emil Kakkis contends the agency’s recruitment challenges, high turnover rates and a lack of expertise on the diseases for which reviewers are evaluating drugs have created a disconnect between FDA leadership’s stated willingness to permit accelerated approval for gene therapy and what review divisions are doing on the ground.
No AdComm Puts Sarepta On Path To Blockbuster Success With Duchenne Gene Therapy
The US FDA’s waiving of an advisory committee is another promising signal that Sarepta's Duchenne gene therapy SRP-9001 could be approved on 29 May and set it up to become a bigger earner than Novartis’s Zolgensma.